Gapping up
In reaction to strong earnings/guidance:
- FDX +11.3%, CDMO +6.6%, SNN +2.3% (provides update on second quarter trading), STZ +2.3%
Other news:
- TTOO +77.2% (announces US launch of molecular diagnostic test for COVID-19)
- AKRO +43.5% (announces positive Phase 2 data)
- MNOV +15.5% (Investigational New Drug Application for MN-166 (ibudilast) for prevention of Acute Respiratory Distress Syndrome (ARDS) has been accepted and is now open)
- ZYNE +10.4% (modestly rebounding following yesterday's 48% decline)
- BYND +9.9% (to launch sales of patties in China)
- BGNE +5.1% (has begun commercialization of XGEVA in China)
- UPS +4.4% (in sympathy with FDX strong earnings)
- AXGN +2.8% (announces financing agreement with Oberland Capital and provides preliminary, estimated revenue for the second quarter ended June 30, 2020)
- XPO +2.5% (in sympathy with FDX strong earnings)
- PEB +1.7% (reports Q2 operating trends)
Analyst comments:
- SAIL +2.6% (upgraded to Buy from Sell at Goldman)
- NEP +2% (upgraded to Buy at Goldman and added to Conviction Buy List)
- CCOI +1.2% (upgraded to Buy from Hold at SunTrust)
- DKNG +0.9% (initiated with an Overweight at Stephens)
- CMCSA +0.8% (upgraded to Outperform from Mkt Perform at Bernstein)
- SQ +0.5% (upgraded to Buy from Neutral at Rosenblatt)